Results 1 to 10 of about 1,576,668 (338)

Interleukin (IL)-1/IL-6-Inhibitor-Associated Drug Reaction With Eosinophilia and Systemic Symptoms (DReSS) in Systemic Inflammatory Illnesses. [PDF]

J Allergy Clin Immunol Pract
Background: After introducing IL-1/IL-6 inhibitors, some patients with Still and Still-like disease developed unusual, often fatal, pulmonary disease. This complication was associated with scoring as DReSS (drug reaction with eosinophilia and systemic ...
Saper VE, Tian L, Verstegen RHJ, Conrad CK, Cidon M, Hopper RK, Kuo CS, Osoegawa K, Baszis K, Bingham CA, Ferguson I, Hahn T, Horne A, Isupova EA, Jones JT, Kasapcopur Ö, Klein-Gitelman MS, Kostik MM, Ozen S, Phadke O, Prahalad S, Randell RL, Sener S, Stingl C, Abdul-Aziz R, Akoghlanian S, Al Julandani D, Alvarez MB, Bader-Meunier B, Balay-Dustrude EE, Balboni I, Baxter SK, Berard RA, Bhattad S, Bolaria R, Boneparth A, Cassidy EA, Co DO, Collins KP, Dancey P, Dickinson AM, Edelheit BS, Espada G, Flanagan ER, Imundo LF, Jindal AK, Kim HA, Klaus G, Lake C, Lapin WB, Lawson EF, Marmor I, Mombourquette J, Ogunjimi B, Olveda R, Ombrello MJ, Onel K, Poholek C, Ramanan AV, Ravelli A, Reinhardt A, Robinson AD, Rouster-Stevens K, Saad N, Schneider R, Selmanovic V, Sefic Pasic I, Shenoi S, Shilo NR, Soep JB, Sura A, Taber SF, Tesher M, Tibaldi J, Torok KS, Tsin CM, Vasquez-Canizares N, Villacis Nunez DS, Way EE, Whitehead B, Zemel LS, Sharma S, Fernández-Viña MA, Mellins ED, CARRA Registry Investigators.   +84 more
europepmc   +8 more sources

Characterization of the Interleukin (IL)-6 Inhibitor IL-6-RFP: fused receptor domains act as high affinity cytokine-binding proteins. [PDF]

Journal of Biological Chemistry, 2007
peer reviewedAlthough fusion proteins of the extracellular parts of receptor subunits termed cytokine traps turned out to be promising cytokine inhibitors for anti-cytokine therapies, their mode of action has not been analyzed.
Lauks, Heike, Wiesinger, Monique Yvonne, Vogt, Michael, Schmalzing, Gunther, WIESINGER, Monique, Wiesinger, Monique Y., Heinrich, Peter C., Metz, Silke, Muller-Newen, Gerhard, Heinrich, Peter   +9 more
core   +3 more sources

Development of an IL-6 inhibitor based on the functional analysis of murine IL-6Ralpha(1).

Chemistry & Biology, 2009
peer reviewedDysregulated cytokine production contributes to inflammatory and proliferative diseases. Therefore, inhibition of proinflammatory mediators such as TNF, IL-1, and IL-6 is of great clinical relevance. Actual strategies are aimed at preventing
Wiesinger, Monique Yvonne, Kuster, Andrea, WIESINGER, Monique, Recker, Tobias, HAAN, Serge, Wiesinger, Monique Y., Kauffmann, Maria-Elisabeth, Heinrich, Peter C., Muller-Newen, Gerhard, Wuller, Stefan, Heinrich, Peter   +10 more
core   +6 more sources

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC [PDF]

Journal for ImmunoTherapy of Cancer, 2020
Background Blood-based biomarkers of anti-solid tumor immune checkpoint blockade (ICB) response are lacking. We hypothesized that changes in systemic cytokine levels with the initial doses of programmed cell death protein 1 (PD-1) pathway inhibitors ...
Mariano Severgnini, Biagio Ricciuti, Alissa Keegan, Padric Garden, Limor Cohen, Reiko Nishihara, Anika Adeni, Cloud Paweletz, Julianna Supplee, Pasi A Jänne, Mark M Awad, David R Walt   +11 more
doaj   +4 more sources

Water intake regulates mucosal immunity in rat jejunal villi via IL‐1β, IL‐6, and IL‐10 [PDF]

Physiological Reports
We had demonstrated that the intragastric administration of distilled water increased male rat jejunal lymph flow and interleukin‐22 levels in the lymph, resulting in the promotion of innate immunity.
Norika Kuneshita, Yuki Sakai, Moyuru Hayashi, Tomomi Watanabe‐Asaka, Daisuke Maejima, Yoshiko Kawai, Toshio Ohhashi   +6 more
doaj   +2 more sources

HSP70 inhibitors upregulate prostaglandin E1-induced synthesis of interleukin-6 in osteoblasts.

PLoS ONE, 2022
Interleukin-6 (IL-6) is a pro-inflammatory and bone-resorptive cytokine that also regulates bone formation. We previously showed that prostaglandin E1 (PGE1) induces the synthesis of IL-6 by activating p44/p42 mitogen-activated protein kinase (MAPK ...
Gen Kuroyanagi, Junko Tachi, Kazuhiko Fujita, Tetsu Kawabata, Go Sakai, Daiki Nakashima, Woo Kim, Kumiko Tanabe, Rie Matsushima-Nishiwaki, Takanobu Otsuka, Hiroki Iida, Osamu Kozawa, Haruhiko Tokuda   +12 more
doaj   +3 more sources

Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?

Atherosclerosis Plus, 2023
Background and aims: Lipoprotein(a) [Lp(a)] and interleuking-6 (IL-6), an inflammation biomarker, have been established as distinct targets of the residual atherosclerotic cardiovascular disease (ASCVD) risk.
Anastasios Makris, Fotios Barkas, Petros P. Sfikakis, Evangelos Liberopoulos, Theodosios D. Filippatos, Kausik K. Ray, Aris P. Agouridis   +6 more
doaj   +1 more source

Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study

Frontiers in Immunology, 2023
BackgroundThe ORAL Surveillance trial showed a potentially higher incidence of malignancy and major adverse cardiovascular events (MACEs) associated with tofacitinib than those associated with tumor necrosis factor (TNF) inhibitors (TNFis).
Shuhei Yoshida, Masayuki Miyata, Eiji Suzuki, Takashi Kanno, Yuya Sumichika, Kenji Saito, Haruki Matsumoto, Jumpei Temmoku, Yuya Fujita, Naoki Matsuoka, Tomoyuki Asano, Shuzo Sato, Kiyoshi Migita   +12 more
doaj   +1 more source

Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab)

Научно-практическая ревматология, 2023
Aim. Switching to another biologic with the same mode of action provides greater opportunity for long-term management of patients with rheumatoid arthritis (RA).
A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Y. Y. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, I. N. Kushnir, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, P. A. Shesternya, N. V. Yudina, E. Feist, E. L. Nasonov   +16 more
doaj   +1 more source

SEVERE HYPOFIBRINOGENEMIA IN A PATIENT WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB: CASE-BASED REVIEW

Anti-Aging Eastern Europe, 2023
The Giant cell arteritis (GCA) is the most common form of systemic vasculitis in elderly patients. The treatment includes high doses of steroids and interleukin (IL)-6 inhibitor tocilizumab, especially in refractory or relapsing disease or in cases where
Željka Kardum, Ana Šimac, Kristina Frketić Marović, Ana Marija Masle, Jasminka MIlas Ahić   +4 more
doaj   +1 more source